Pignot Géraldine (@pignotg) 's Twitter Profile
Pignot Géraldine

@pignotg

urologue à L'institut Paoli-Calmettes à Marseille

ID: 1228081742784761856

calendar_today13-02-2020 22:21:31

3,3K Tweet

1,1K Followers

231 Following

OncoAlert (@oncoalert) 's Twitter Profile Photo

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma link.springer.com/article/10.100… This multicenter retrospective study aimed to assess the oncological outcomes of delayed nephrectomy after

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma 

link.springer.com/article/10.100…

This multicenter retrospective study aimed to assess the oncological outcomes of delayed nephrectomy after
Riccardo Campi (@ric_campi) 's Twitter Profile Photo

Our first Florence Multidisciplinary Expert Meeting on RCC Long story short: 2 days full of #science & #emotions, surrounded by experts and brilliant researchers in the field, all part of a wonderful #family aiming to share knowledge and expertise to advance #RCC care. Embraced by the beauty of Florence.

Mirrors of Medicine (@mirrorsmed) 's Twitter Profile Photo

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial out on JCO ascopubs.org/doi/abs/10.120… Phase II trial evaluated the safety and efficacy of neoadjuvant

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: 
the iNDUCT trial out on JCO

ascopubs.org/doi/abs/10.120…

Phase II trial evaluated the safety and efficacy of neoadjuvant
Mirrors of Medicine (@mirrorsmed) 's Twitter Profile Photo

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial ascopubs.org/doi/10.1200/JC… This phase II trial evaluated the safety and efficacy of neoadjuvant

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial

ascopubs.org/doi/10.1200/JC…

This phase II trial evaluated the safety and efficacy of neoadjuvant
Shilpa Gupta (@shilpaonc) 's Twitter Profile Photo

Elegant discussion by Pignot Géraldine putting into perspective importance of risk/safety assessment & NIAGARA trial showed no additional toxicity with durvalumab. Gem Cis Durva is the new SOC. Raises question of possibly overstatement with adjuvant IO in NIAGARA trial for patients

European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

📺EAU25: EAUTV on AURORAX 0087A study UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Saeed Dabestani on the AURORAX 0087A study. ▶️ Watch the conversation here: eaucongress.uroweb.org/eau25-eautv-on…

UNIPA (@syndicat_unipa) 's Twitter Profile Photo

👩‍🦰👩‍⚕Donner des ELLES à la santé : une réalité portée par le Syndicat UNIPA ! Aujourd’hui, notre secrétaire générale Lise Mantisi a brillamment représenté le syndicat des Infirmiers en Pratique Avancée (UNIPA) lors de la table ronde “Égalité professionnelle à l’hôpital :

👩‍🦰👩‍⚕Donner des ELLES à la santé : une réalité portée par le Syndicat UNIPA !

Aujourd’hui, notre secrétaire générale Lise Mantisi a brillamment représenté le syndicat des Infirmiers en Pratique Avancée (UNIPA) lors de la table ronde “Égalité professionnelle à l’hôpital :
NEJM (@nejm) 's Twitter Profile Photo

The authors of a new Perspective argue that severing the long-standing ties and scientific collaborations between the United States and the World Health Organization (WHO) and slashing U.S. financial support will have catastrophic effects on both domestic and global health. Read the full Perspective:

The authors of a new Perspective argue that severing the long-standing ties and scientific collaborations between the United States and the <a href="/WHO/">World Health Organization (WHO)</a> and slashing U.S. financial support will have catastrophic effects on both domestic and global health. Read the full Perspective:
@FOCUS_meeting (@focusmeeting) 's Twitter Profile Photo

Le programme de FOCUS 2025 meets Spain est disponible : focus-meeting.fr/programme/ Présidents @ecastromarcos et Karim Bensalah Nous vous attendons nombreux pour cette nouvelle édition ! 🗓 9 et 10 octobre 2025 📍Centre de congrès Pierre Baudis, Toulouse

Le programme de FOCUS 2025 meets Spain est disponible : focus-meeting.fr/programme/
Présidents @ecastromarcos et <a href="/kbensalah35/">Karim Bensalah</a>
Nous vous attendons nombreux pour cette nouvelle édition !
🗓 9 et 10 octobre 2025
📍Centre de congrès Pierre Baudis, Toulouse
Mirrors of Medicine (@mirrorsmed) 's Twitter Profile Photo

Let's kick off #RENALC25 with a first case challenge! Manuel has a small renal mass in his only functional kidney. What now? 👉 Check out the case, vote on your preferred treatment option: renalc.mirrorsmed.org/en/single-case… and see what Dr. Pignot Géraldine would do!📽️ Want to be part of more case

Let's kick off #RENALC25 with a first case challenge!  Manuel has a small renal mass in his only functional kidney. What now? 👉 Check out the case, vote on your preferred treatment option: renalc.mirrorsmed.org/en/single-case… and see what Dr. <a href="/PignotG/">Pignot Géraldine</a> would do!📽️
Want to be part of more case
Mirrors of Medicine (@mirrorsmed) 's Twitter Profile Photo

How exciting to see all these new data at #ASCO25! 👀 Interested to hear how these data are translated to your clinical practice? 👂 At the Global Forum on GU Oncology, the impact of the latest findings on #RenalCancer, #BladderCancer and #ProstateCancer are discussed in a

How exciting to see all these new data at #ASCO25! 👀 Interested to hear how these data are translated to your clinical practice? 👂 
At the Global Forum on GU Oncology, the impact of the latest findings on #RenalCancer, #BladderCancer and #ProstateCancer are discussed in a
Simone Crivellaro (@simonecrivella2) 's Twitter Profile Photo

Friday : #SP case obs at UIC Urology with Markus Grabbert 🇩🇪, Saturday : boat trip with Alberto Briganti 🇮🇹 & Maria J. Ribal 🇪🇸, Monday with Andrea Tubaro 🇮🇹 & Pignot Géraldine 🇫🇷, Tuesday : on my way to #CILR25 #international learning and teaching is at the base of our community.

Friday : #SP case obs at <a href="/UICUrol/">UIC Urology</a> with <a href="/MarkusGrabbert/">Markus Grabbert</a> 🇩🇪, Saturday : boat trip with <a href="/Albert0Briganti/">Alberto Briganti</a> 🇮🇹  &amp; <a href="/MariaJRibal/">Maria J. Ribal</a>  🇪🇸, Monday with <a href="/AndreaTubaro/">Andrea Tubaro</a> 🇮🇹 &amp; <a href="/PignotG/">Pignot Géraldine</a> 🇫🇷, Tuesday : on my way to #CILR25 #international learning and teaching is at the base of our community.
Pignot Géraldine (@pignotg) 's Twitter Profile Photo

Amazing presentation of Ploussard Guillaume at JUM / Marseille Key messages : 📛 No de-escalation for high risk patients if negative PET-PSMA (NPV 80% in this population with a high prevalence, suggesting that we can miss 20% of pN+ without eLNPD) ❓️What about intermediate risk ?

Amazing presentation of <a href="/GPloussard/">Ploussard Guillaume</a> at JUM / Marseille 
Key messages :
📛 No de-escalation for high risk patients if negative PET-PSMA (NPV 80% in this population with a high prevalence, suggesting that we can miss 20% of pN+ without eLNPD)
❓️What about intermediate risk ?